CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Lundin, Jeanette; Österborg, Anders; Brittinger, G.; Crowther, Derek; Dombret, Hervé; Engert, Andreas; Epenetos, A. A.; Gisselbrecht, Christian; Huhn, D.; Jaeger, Ulrich; Thomas, Jacob G.; Marcus, Robert; Nissen, Nicholas; Poynton, Christopher H.; Rankin, Elaine M.; Stahel, R.; Uppenkamp, Michael; Willemze, R.; Mellstedt, Håkan

doi:10.1200/jco.1998.16.10.3257

Cited by 244 publications

(128 citation statements)

References 13 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…6 The monoclonal antibody alemtuzumab, a humanized anti-CD52 antibody, has shown activity alone and in combination for patients with refractory CLL with an overall response rate of 33%, and was also proven effective in initial treatment of CLL patients, with approximately 80% of patients achieving durable responses. [7][8][9][10][11][12] Encouraging results have been published for the in vivo purging of residual disease after alemtuzumab consolidation. 13 Alemtuzumab lyses normal and malignant lymphocytes by antibody-dependent cellular cytotoxicity (ADCC), complement activation and direct induction of apoptosis.…”

Section: Introductionmentioning

confidence: 99%

“…[14][15][16][17] Besides effects against malignant lymphocytes in blood, alemtuzumab shows activity against lymphocytes derived from bone marrow and spleen, but is less active against nodal or extranodal masses. 9 Since CD52 is not expressed on CD34 þ hematopoietic stem cells, therapy with alemtuzumab does not preclude stem cell collection and further high-dose concepts. 18 Therefore, the aim of this study was to assess the safety profile, feasibility and efficacy of alemtuzumab as a consolidation therapy to improve the quality of remission and to eradicate minimal residual disease in patients responding to a first-line fludarabine-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Ritgen²,

et al. 2004

Self Cite

View full text Add to dashboard Cite

Patients with CLL responding to initial chemotherapy with fludarabine alone (F) or in combination with cyclophosphamide (FC) were randomized for treatment with alemtuzumab (30 mg i.v. TIW, 12 weeks) or observation. Of 21 evaluable patients, 11 were randomized to alemtuzumab before the study was stopped due to severe infections in seven of 11 patients. These infections (one life-threatening pulmonary aspergillosis IV; four CMV reactivations III requiring i.v. ganciclovir; one pulmonary tuberculosis III; one herpes zoster III) were successfully treated and not associated with cumulative dose of alemtuzumab. In the observation arm, one herpes zoster infection II and one sinusitis I were documented. At 6 months after randomization, two patients in the alemtuzumab arm converted to CR, while three patients in the observation arm progressed. After alemtuzumab treatment, five of six patients achieved a molecular remission in peripheral blood while all patients in the observation arm remained MRD-positive (P ¼ 0.048). At 21.4 months median follow-up, patients receiving alemtuzumab showed a significant longer progression-free survival (no progression vs mean 24.7 months; P ¼ 0.036). In conclusion, a consolidation therapy with alemtuzumab is able to achieve molecular remissions and longer survival in CLL, but a safe treatment regimen needs to be determined.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Ritgen²,

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is a humanized monoclonal antibody that targets CD52, a cell surface protein present at high density on most normal and malignant B and T lymphocytes. As a single agent, alemtuzumab has been used to treat pretreated cutaneous/PTCL with overall response rate (ORR) of 36-60% [28][29][30]. A higher ORR of 50% was observed in the treatment of mycoses fungoides [30].…”

Section: Introductionmentioning

confidence: 99%

“…As a single agent, alemtuzumab has been used to treat pretreated cutaneous/PTCL with overall response rate (ORR) of 36-60% [28][29][30]. A higher ORR of 50% was observed in the treatment of mycoses fungoides [30]. Successful treatment with alemtuzumab has been reported in the subtypes of mature T-cell neoplasms, such as Lennert's lymphoma [31], hepatosplenic gammadelta T-cell lymphoma [32], angioimmunoblastic T-cell lymphoma [33] and primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma [34].…”

Section: Introductionmentioning

confidence: 99%

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Kuan

Chang

Lau

et al. 2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

We report our experience in using six cycles of hyperCVAD in combination with alemtuzumab for the treatment of aggressive T-cell and NK/T-cell neoplasms. Seven females and six males with the median age of 41 (range 18-60) diagnosed with T-cell acute lymphoblastic lymphoma and peripheral T-cell and NK/T-cell neoplasms (n PTCL = 6, n T-cell ALL = 3, n NK/T-cell neoplasms = 4) from 2006 to 2008 were treated with alemtuzumab-hyperCVAD regimen. A total of nine patients (69%) responded to the regimen, with seven achieved complete remission and two achieved partial remission. The median progression free survival and overall survival duration among the responders with complete remission were 12.9 and 24.9 months respectively. The incidence of relapse among the responders was 44% and the overall survival rate was 23%. Only four (31%) patients completed the six cycles of alemtuzumab-hyperCVAD. Others were stopped earlier due to progressive disease (n = 2), cytomegalovirus (CMV) reactivation and/or disease (n = 3), death not due to disease (n = 2), and patient's refusal to continue alemtuzumab (n = 2). The incidence of death not due to disease, CMV reactivation and recurrent CMV reactivation were 50, 50 and 17%, respectively. This study shows that alemtuzumab in combination with hyperCVAD regimen is a feasible regimen but with high toxicity. The toxicity might be reduced with the incorporation of filgrastim and use of valganciclovir as CMV prophylaxis.

show abstract

“…18 Studies in non-Hodgkin's lymphoma were less successful because alemtuzumab did not have a significant impact on bulky lymph nodes at the doses used, though it still cleared tumour cells from blood and bone marrow. 19 …”

Section: Alemtuzumab As Treatment For Lymphoid Malignanciesmentioning

confidence: 99%

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Hale

Slavin

Goldman

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the tumour burden in B-CLL, a new niche may be found -as a potentially curative agent in which its tumour purging ability in vivo combines with its role as a conditioning agent in nonmyeloablative transplantation. Review of the literature shows that alemtuzumab has unique advantages as a method of depleting malignant lymphocytes, including those in patients resistant to conventional chemotherapy. Alemtuzumab can also be used in BMT for depletion of normal T and B lymphocytes of both the recipient and donor for prevention of graft rejection and GVHD. It allows good stem cell recovery with resultant rapid engraftment, has a low risk of EBVtriggered secondary malignancy and does not interfere with blood stem cell mobilisation. As a method of eliminating the malignant clone in B-CLL, alemtuzumab has shown remarkable efficacy in heavily pre-treated patients, a number of whom have progressed to autologous or allogeneic transplantation. Efficacy data are shown within the context of other transplantation data for B-CLL. These results indicate that the combination of tumour-depleting and immunosuppressive properties of alemtuzumab should be explored, with the hope of providing improved treatment options for elderly patients with advanced B-CLL or indolent lymphoma whose prognosis is too poor currently to allow treatment with traditional regimens of high-dose myeloablative chemotherapy.

show abstract

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Cited by 244 publications

References 13 publications

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Contact Info

Product

Resources

About